The purpose of this study was to report the effects of smoking on retinal vascular parameters. Methods: In this cross-sectional study design, 24 smokers were included as a study group and 26 age-and sex-matched non-smokers as a control group. A detailed ophthalmic examination including review of medical history, visual acuity testing, intraocular pressure measurement by Goldmann applanation tonometry, ocular movement and pupillary reflex examination, slitlamp biomicroscopy as well as dilated funduscopic examination were undertaken in all participants. Participants underwent optical coherence tomography angiography (OCT-A) scanning with RTVue XR Avanti AngioVue OCT-A (Optovue, Fremont, CA, USA) as well as the measurement of axial length using an AL Scan (Nidek Co., Ltd., Gamagori, Japan). Results: The study comprised of 18 men and six women with a mean age of 28.1 AE 4.8 years in the study group and 19 men and seven women with a mean age of 27.4 AE 2.7 years in the control group. The mean exposure to cigarette smoking was 3.3 AE 1.0 pack-years. Total vascular density, parafoveal vascular density and perifoveal vascular density in the deep capillary plexus observed with OCT-A were significantly lower in the smoking group compared to the control group (p = 0.02, 0.01 and 0.01, respectively). Conclusion: Retinal vascular changes caused by cigarette smoking may occur even at low pack-year exposure. These changes, which can be demonstrated by OCT-A, may reflect the early impact of cigarette smoking on the microvascular system.

Background: The Steno hypothesis states that changes in basement membrane anionic charge leads to diabetic microvascular complications. In diabetic nephropathy, loss of basement membrane glycosaminoglycans and the association between glomerular basement membrane heparan sulphate and proteinuria has been documented. A correlation between erythrocyte surface and the glomerular capillary wall charges has also been observed.

Purpose: Retinopathy of prematurity (ROP) is the leading cause of preventable blindness in premature infants. Antivascular endothelial growth factor (anti-VEGF) therapy has been used increasingly in treatment as a pharmacological alternative to laser therapy. In this study, we evaluate the results of low-dose anti-VEGF treatments. Methods: Design: Retrospective--observational study. Infants who had been evaluated for ROP disease between February 2016 and February 2017 were assessed. We retrospectively reviewed the ROP stages, treatment results, and complications. Laser photocoagulation (LPC) and intravitreal bevacizumab (0.16 mg IVB) were used for treatment and fundus fluorescein angiography (FFA) was also performed in some of the cases. Results: IVB was applied to 43 infants. A macular hole was seen in one infant's eye after IVB. LPC was applied to avascular areas in 21 infants. In three patients, persistence of the disease was observed after administration of a low dose of IVB. Additional LFK was performed in these patients. None of the infants who received LPC had any complications. Conclusion: IVB is increasingly becoming the first-line treatment for ROP. For severe ROP, 0.16 mg IVB is effective. Using LPC to treat avascular areas after 70 weeks’ gestational age (GA) may decrease the risk of late recurrence and appears to be a safe treatment to use.